Oramed Pharmaceuticals, the developer of the Oravax oral COVID-19 vaccine candidate, has announced a partnership with Mexico’s Genomma Lab Internacional to help fast-track a Phase II clinical trial and gain emergency use authorization in the Latin American country. Read more here.
Oramed’s Oravax Medical and Genomma Lab Internacional announce joint venture to develop and commercialize vaccine for Latin America. Read more here.
Oramed Pharmaceuticals Inc. (ORMP) and Genomma Lab Internacional announced the formation of a 50/50 joint venture between Genomma Lab and Oramed’s majority-owned subsidiary Oravax Medical to develop and commercialize Oravax’s COVID-19 vaccine candidate in Mexico. Oramed and Genomma Lab also announced their plans to enter into a $20 million share swap. Genomma Lab has also […]
NEW YORK, Nov. 23, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled and randomized over 75% of the 675 patients planned for its Phase 3 ORA-D-013-1 study of its oral insulin capsule ORMD-0801 […]